Company intelligence / Profile preview
Halo-Bio RNAi Therapeutics
Seattle, Washington, United Stateshalo-bio.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Halo-Bio RNAi Therapeutics is an early-stage biopharma developing an RNAi platform for multi-gene targeting therapeutics using proprietary MV-RNA triggers and nanoparticle delivery, with preclinical studies in cancer and infectious diseases; clinical results not disclosed as of 2025.
- Therapeutic areas
- OncologyRare DiseasesInfectious Diseases
- Modalities
- Small interfering RNARNA therapyNanoparticle
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Tekmira (licensing of MV-RNA platform)
Beyond the preview
Go deeper on Halo-Bio RNAi Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Halo-Bio RNAi Therapeutics.